The AMR Industry Alliance brings together over 100 research-based pharmaceutical, generics, biotech and diagnostic companies and associations, to drive and measure the life-sciences’ industry progress to curb #AMR. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Declaration (January 2016) and the Roadmap (September 2016) and measures industry’s progress in the fight against antimicrobial resistance. A first progress report was launched in January 2018, and tracked progress in four different areas (Research and Science, Access, Appropriate Use, and Environment), identify gaps and set targets for the future. The Alliance’s reporting will provide timely and concrete insights to inform decision-making at global level and help to assess what are the key hurdles impeding action, and facilitate collaboration between the public and private sectors: https://www.amrindustryalliance.org/progress-report/. The second progress report will be launched in January 2020.